C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation
Chemoresistance is a major unmet clinical obstacle in ovarian cancer treatment. Epigenetics plays a pivotal role in regulating the malignant phenotype, and has the potential in developing therapeutically valuable targets that improve the dismal outcome of this disease. Here we show that a series of transcription factors, including C/EBPβ, GCM1, and GATA1, could act as potential modulators of histone methylation in tumor cells. Of note, C/EBPβ, an independent prognostic factor for patients with ovarian cancer, mediates an important mechanism through which epigenetic enzyme modifies groups of functionally related genes in a context-dependent manner. By recruiting the methyltransferase DOT1L, C/EBPβ can maintain an open chromatin state by H3K79 methylation of multiple drug-resistance genes, thereby augmenting the chemoresistance of tumor cells. Therefore, we propose a new path against cancer epigenetics in which identifying and targeting the key regulators of epigenetics such as C/EBPβ may provide more precise therapeutic options in ovarian cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Nature communications - 9(2018), 1 vom: 30. Apr., Seite 1739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Dan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.12.2018 Date Revised 08.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-018-03590-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283602562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283602562 | ||
| 003 | DE-627 | ||
| 005 | 20231225041256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-018-03590-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0945.xml |
| 035 | |a (DE-627)NLM283602562 | ||
| 035 | |a (NLM)29712898 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Dan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2018 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chemoresistance is a major unmet clinical obstacle in ovarian cancer treatment. Epigenetics plays a pivotal role in regulating the malignant phenotype, and has the potential in developing therapeutically valuable targets that improve the dismal outcome of this disease. Here we show that a series of transcription factors, including C/EBPβ, GCM1, and GATA1, could act as potential modulators of histone methylation in tumor cells. Of note, C/EBPβ, an independent prognostic factor for patients with ovarian cancer, mediates an important mechanism through which epigenetic enzyme modifies groups of functionally related genes in a context-dependent manner. By recruiting the methyltransferase DOT1L, C/EBPβ can maintain an open chromatin state by H3K79 methylation of multiple drug-resistance genes, thereby augmenting the chemoresistance of tumor cells. Therefore, we propose a new path against cancer epigenetics in which identifying and targeting the key regulators of epigenetics such as C/EBPβ may provide more precise therapeutic options in ovarian cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CCAAT-Enhancer-Binding Protein-beta |2 NLM | |
| 650 | 7 | |a Chromatin |2 NLM | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a GATA1 Transcription Factor |2 NLM | |
| 650 | 7 | |a GATA1 protein, human |2 NLM | |
| 650 | 7 | |a GATA4 Transcription Factor |2 NLM | |
| 650 | 7 | |a GATA4 protein, human |2 NLM | |
| 650 | 7 | |a GCM1 protein, human |2 NLM | |
| 650 | 7 | |a Histones |2 NLM | |
| 650 | 7 | |a IRF3 protein, human |2 NLM | |
| 650 | 7 | |a Interferon Regulatory Factor-3 |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a DOT1L protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a Methyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.1.1.- |2 NLM | |
| 650 | 7 | |a Histone-Lysine N-Methyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.1.1.43 |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Zhang, Xiao-Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Meng-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Can-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Dong-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Xi, Bi-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Jia-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zong-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Xin-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Xi, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jian-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Zuo-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ding |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Qing-Lei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 9(2018), 1 vom: 30. Apr., Seite 1739 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2018 |g number:1 |g day:30 |g month:04 |g pages:1739 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-018-03590-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2018 |e 1 |b 30 |c 04 |h 1739 | ||